Blood, serum and plasma represent accessible sources of data about physiological and pathological status. In Arrhythmogenic Cardiomyopathy (ACM), circulating nucleated cells are routinely employed for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, and these include inflammatory cytokines, markers of myocardial dysfunction and damage, microRNAs.
This review summarizes the current information that can be retrieved from the blood of ACM patients and consider the future prospects. The current knowledge of circulating factors in ACM blood is limited, and clinical application is restricted to genetics and a few HF biomarkers.
Improvements of knowledge about circulating factors may provide non-invasive means to simplify and improve the diagnosis, prognosis prediction and management of ACM patients.